Coronavirus Update: Moderna Still Confident Of November Readout
Neck And Neck With Pfizer
Executive Summary
The company said its own calculations suggested a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
You may also be interested in...
Coronavirus Update: Moderna Ready For Interim Analysis, Brazil Resumes SinoVac Trial
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.
Pipeline Watch: Six Approvals And 26 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Changes At The Top At Aileron, KalVista And More
Recent moves in the industry include new chief medical officers at Rigel Pharmaceuticals and FibroGen, while Aileron Therapeutics and KalVista get new CEOs.